与免疫检查点抑制剂相关的胆道疾病:FDA不良事件报告系统 (FAERS) 数据库的药监测分析
Shiju Wei1, Zhenyu Zhang1, Xuhua Song2
1The Second Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, People's Republic of China.
Journal of chemotherapy (Florence, Italy)
|January 13, 2026
概括
免疫检查点抑制剂 (ICI) 显著增加严重胆道疾病的风险. 早期监测至关重要,特别是接受ICI治疗的高风险患者.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 免疫检查点抑制剂 (ICI) 是广泛使用的癌症疗法.
- 严重的胆道疾病 (BDs) 曾经与ICI使用有关.
研究的目的:
- 量化ICI使用与BD之间的关联.
- 为了确定特定的ICI类型和与增加BD风险相关的患者因素.
主要方法:
- 从2015年第一季度到2025年第一季度对FAERS数据库的分析.
- 标准化的MedDRA查询发现了4,405个BD病例.
- 报告的赔率比率 (ROR) 被计算出来以评估风险.
主要成果:
- ICI显示出与BD的显著整体关联 (ROR 3.37).
- 抗PD-1/PD-L1单疗法和组合疗法呈现较高的风险,胆道缩和免疫介导胆道炎的极端ROR.
- 19.9%的BD病例是致命的,致命病例的发病时间较早.
结论:
- ICI治疗与严重的胆道损伤密切相关.
- 风险分层和早期胆道监测对于ICI患者至关重要,特别是那些具有特定风险因素的患者.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
179
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Chronic Bowel Disorders: Introduction
743
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
743
Therapeutic Drug Monitoring: Affecting Factors
196
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196
Hepatic Drug Excretion: Influencing Factors
518
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
518


